CoChat

Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Objective The Vienna Challenge Chamber (VCC) offers a controlled and controllable paradigm in which to reproducibly evaluate the efficacy of anti-allergic treatment. The aim of this study was to assess the efficacy of the novel intranasal corticosteroid fluticasone furoate (FF) in the VCC. Methods The single-centre, randomised, double-blind, placebo-controlled, two-period crossover study was conducted in 59 adult males with grass pollen allergic rhinitis (AR). Patients received either Fluticasone furoate 200 mcg once-daily, or placebo intranasally for 8 days. AR symptoms were induced during 4-hour allergen challenges with grass pollen in the VCC at the end of each 8-day treatment period. A first challenge was conducted at 1-5 hours post-dose, followed by a second challenge at 22-26 hours post-dose. The primary endpoint was total nasal symptom score (TNSS; sum of itch, sneeze, rhinorrhoea, obstruction symptoms assessed on a categorical scale of 0-3) weighted mean over 2-5 hours post-dose. Secondary endpoints included: TNSS weighted mean over 23-26 hours post-dose and global symptom score, eye symptom score, nasal secretions and nasal airflow weighted means over 2-5 and 23-26 hours post-dose. Results Fluticasone furoate showed consistent attenuation of AR symptoms in both the early and late challenges. Compared with placebo, weighted mean of TNSS was reduced on average by 4.14 point-scores at 2-5 hours post-dose and 3.63 point scores at 23-26 hours post-dose. These positive eff…

Overview

Integrity signals

Registry

Crossref · 10.1185/03007990802155792

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Research works printed but not linked: 5

  1. Horak F, 1987, Wien Klin Wochenschr, 99, 509
  2. Horak F, 2005, Ann Allergy Asthma Immunol, 94, 104
  3. Horak F, 2004, Drug Res, 54, 666
  4. Horak F, 2000, Drug Research, 50, 1099
  5. Horak F, 1998, J Investig Allergol Clin Immunol, 8, 165

Cited by

See all 36

Metadata

Authors
Zieglmayer, P., Zieglmayer, R., Bareille, P., Rousell, V., Salmon, E., & Horak, F.
Affiliations
  • Vienna Challenge Chamber (AT)
  • GlaxoSmithKline (United Kingdom) (GB)
Corresponding author
Zieglmayer, Petra
Venue
Current Medical Research and Opinion
Published
2008-05-28
Volume
24
Issue
6
Pages
1833-1840
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2158466843
Cited by
35
References
19
Citations by year
2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 7 · 2018: 1 · 2016: 3 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 2
FWCI
0.86
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
Keywords
fluticasone furoate, allergic rhinitis, grass pollen allergy, intranasal corticosteroids, allergen challenge, nasal symptom score, ocular symptoms, rhinorrhea, nasal obstruction
MeSH terms
Adolescent, Adult, Androstadienes, Double-Blind Method, Environmental Exposure, Glucocorticoids, Poaceae, Rhinitis, Allergic, Seasonal, Humans, Male, Middle Aged, Treatment Outcome, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. https://app.cochat.ai/papers/10.1185/03007990802155792
The paper
Zieglmayer, P., Zieglmayer, R., Bareille, P., Rousell, V., Salmon, E., & Horak, F. (2008). Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Current Medical Research and Opinion. https://doi.org/10.1185/03007990802155792

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.